Bisocor

Bisoprolol fumarate

2.5 & 5 mg: Stable chronic heart failure w/ reduced systolic left ventricular function. 5 mg: HTN & CHD.

HTN & angina Initially 5 mg once daily, may be increased to 10 mg once daily. Max: 20 mg once daily. Stable chronic heart failure 1.25 mg once daily for 1st wk then 2.5 mg once daily for 2nd wk then 3.75 mg once daily for 3rd wk then 5 mg once daily for 4th-7th wk then 7.5 mg once daily for 8th-11th wk then 10 mg once daily for maintenance therapy. Max: 10 mg once daily. Severe renal (CrCl <20 mL/min) & hepatic impairment Max: 10 mg once daily.

May be taken with or without food.

Hypersensitivity. Acute heart failure or during episodes of heart failure decompensation; cardiogenic shock; 2nd- or 3rd-degree AV block; sick sinus syndrome; SA block; symptomatic bradycardia & hypotension; severe bronchial asthma or COPD; severe peripheral arterial occlusive disease or Raynaud's syndrome; untreated phaeochromocytoma; metabolic acidosis.

Allergic reactions. DM, cardiogenic shock, 1st degree AV block, Prinzmetal's angina, ongoing desensitisation therapy, strict fasting, peripheral arterial occlusive disease, psoriasis or w/ personal history of psoriasis, bronchial asthma or symptomatic COPD phaechromocytoma, thyrotoxicosis, restrictive cardiomyopathy, congenital or haemodynamically relevant organic valvular heart disease, heart failure & MI w/in last 3 mth. Gradually w/draw therapy before surgery & complete 48 hr prior to anesth. Avoid abrupt discontinuation. Severe renal & hepatic impairment. May affect ability to drive & use machines. Not to be used during pregnancy & not recommended during lactation. Not recommended in childn.

AV conduction disturbances, worsening of preexisting heart failure, bradycardia; feeling of coldness or numbness in extremities, hypotension, orthostatic hypotension; increased triglycerides; sleep disorders, depression, nightmares, hallucinations; dizziness, headache, syncope; reduced tear flow in patient using lenses, conjunctivitis; hearing disorders; bronchospams in patients w/ bronchial asthma or history of obstructive airways disease, allergic rhinitis; GI complaints eg, nausea, vomiting, diarrhoea, constipation; increased ALT & AST, hepatitis; hypersensitivity reactions; provoke or worsen psoriasis or induce psoriasis-like rash, alopecia; muscular weakness & cramps; potency disorders; fatigue, asthenia.

Negative influence on contractility & AV conduction w/ verapamil- & diltiazem-type Ca antagonists. Reduced heart rate & cardiac output w/ centrally-acting antihypertensive drugs eg, clonidine, methyldopa, moxonodine, rilmenidine. Increased risk of hypotension & further deterioration of ventricular pump functions in heart failure patients w/ dihydropyridine type Ca antagonist eg, nifedipine. Potentiated AV conduction time by class I (eg, disopyramide, quinidine) & class III (eg, amiodarone) antiarrhythmic drugs. Increased AV conduction time & risk of bradycardia w/ parasympathomimetic drugs. Intensified blood sugar lowering effect w/ insulin & oral antidiabetic drugs. Attenuated reflex tachycardia w/ anaesth agents. Reduced heart rate & increased AV conduction time w/ digitalis glycosides. Reduced hypotensive effects by NSAIDs. Reduced effects of both agents when used together w/ β-sympathomimetic agents (eg, isoprenaline, dobutamine). Increased BP w/ β- & α-adrenoceptors (eg, noradrenaline, adrenaline). Increased risk of hypotension w/ TCAs, barbiturates, phenothiazines & antihypertensives. Severe postural hypotension w/ moxisylyte. Increased bradycardia w/ mefloquine. Enhanced hypotensive effect & risk for hypertensive crisis w/ MAOIs.

Beta-Blockers

C07AB07 - bisoprolol ; Belongs to the class of selective beta-blocking agents. Used in the treatment of cardiovascular diseases.

B